Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1be…
USD96.33+0.05%vs prev. close
Performance
1W
+2.63%
1M
+22.18%
3M
+25.51%
1Y
+139.09%
YTD
+133.53%
Valuation
P/E
73.0
EPS TTM
1.32
Dividend yield
—
Size and risk
Market cap
$7.6B
Beta
0.08
Price history
KNSA price
USD
Total returnEventsVs index
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
Kiniksa Pharmaceuticals International
KNSA
Drug Manufacturers - Specialty & Generic
Mkt cap (USD bn)
7.6
P/E
73.0
Div yld
—
1W
+2.6%
1M
+22.2%
3M
+25.5%
6M
+70.5%
1Y
+139.1%
YTD
+133.5%
Company
Ticker
Industry
Mkt cap (USD bn)
P/E
Div yld
1W
1M
3M
6M
1Y
YTD
Kiniksa Pharmaceuticals International
KNSA
Drug Manufacturers - Specialty & Generic
7.6
73.0
—
+2.6%
+22.2%
+25.5%
+70.5%
+139.1%
+133.5%
Subscribe to Equity Analytics to compare KNSA with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.